Advertising disclosure — We may earn a commission if you start care through some of these links, at no extra cost to you. How we're funded. Order reflects our editorial rubric and our commercial relationships; scores are ours alone.
Luna Fit
NiceRx review
An accredited, nationwide program with predictable mid-market pricing on both molecules — a dependable if unremarkable choice.
- Semaglutide
- $199/mo
- Tirzepatide
- $299/mo
- Coverage
- All 50 states
- Brand-name
- Compounded only
The Luna Fit scorecard
NiceRx scored on our six women's-health factors. See the methodology.
What we like
- LegitScript-accredited and nationwide
- Both molecules disclosed and predictably priced
- Tirzepatide available for insulin-resistant PCOS
The caveats
- No oral or brand-name option
- General metabolic program without hormone specialization
The bottom line
Best for: Women who want a LegitScript-accredited, all-50-states provider with clear pricing on both molecules. An accredited, nationwide program with predictable mid-market pricing on both molecules — a dependable if unremarkable choice.
Ranked #33 of 80 providers we reviewed for women — see our #1 pick, CoreAge Rx, for comparison. PCOS & hormonal suitability is where NiceRx scores lowest, at 82/100. If that is your sticking point, start with the full field we rank against NiceRx.
Others in NiceRx's score range
The providers scoring closest to NiceRx on the same six factors. One of those comparisons is written out in full: how NiceRx and CoreAge Rx compare on the Luna Fit Score, 8 points apart on the Luna Fit Score. Directly below NiceRx sits AgelessRx at #34 with 84/100 — see what women pick instead of AgelessRx if that is the band you are shopping in.
See all 80 providers we've reviewed for women — ranked on the same rubric, with scores and pricing side by side.
Pricing, states and verification reflect NiceRx's public disclosures at last review; the Luna Fit Score is our editorial judgment per the methodology. Prices change — confirm on NiceRx's site. Not medical advice; see our disclosure.